# PET/MRI in Rectal Cancer

Source: https://onco.cc/trials/nct06057831/  
OnCo record `nct06057831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by AHS Cancer Control Alberta, not yet recruiting.

## Summary

PET/MRI in Rectal Cancer is a phase 2, interventional study registered as NCT06057831 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-05 and due to reach its primary completion in 2029-05. Interventions recorded: Total Neo-adjuvant Therapy; 18FDG-PET/MRI scan. Conditions listed: Rectal Cancer. Primary outcome: The primary endpoint of the study is pathological response (pCR) prediction with PET/MRI.; Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.. Colorectal eligibility wording from the registry: "Patients with histologically proven adenocarcinoma of the rectum". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06057831
- Phase: 2
- Setting: 18FDG-PET/MRI Imaging in Predicting Pathological Response to Total Neo-adjuvant Therapy in Rectal Cancer
- Sponsor: AHS Cancer Control Alberta
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06057831: https://clinicaltrials.gov/study/NCT06057831

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06057831.json